首页> 美国卫生研究院文献>Cell Transplantation >Comparison of Bone Marrow Aspirate Concentrate and Allogenic Human Umbilical Cord Blood Derived Mesenchymal Stem Cell Implantation on Chondral Defect of Knee: Assessment of Clinical and Magnetic Resonance Imaging Outcomes at 2-Year Follow-Up
【2h】

Comparison of Bone Marrow Aspirate Concentrate and Allogenic Human Umbilical Cord Blood Derived Mesenchymal Stem Cell Implantation on Chondral Defect of Knee: Assessment of Clinical and Magnetic Resonance Imaging Outcomes at 2-Year Follow-Up

机译:骨髓抽吸浓缩物和同种异体人脐血血液衍生间充质干细胞植入对膝关胞骨缺损的比较:2年后临床和磁共振成像结果评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Biological repair of cartilage lesions remains a significant clinical challenge. A wide variety of methods involving mesenchymal stem cells (MSCs) have been introduced. Because of the limitation of the results, most of the treatment methods have not yet been approved by the Food and Drug Administration (FDA). However, bone marrow aspirate concentrate (BMAC) and human umbilical cord blood derived mesenchymal stem cells (hUCB-MSCs) implantation were approved by Korea FDA. The aim of this study was to evaluate clinical and magnetic resonance imaging (MRI) outcomes after two different types of MSCs implantation in knee osteoarthritis. Fifty-two patients (52 knees) who underwent cartilage repair surgery using the BMAC (25 knees) and hUCB-MSCs (27 knees) were retrospectively evaluated for 2 years after surgery. Clinical outcomes were evaluated according to the score of visual analogue scale (VAS), the International Knee Documentation Committee (IKDC) subjective, and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Cartilage repair was assessed according to the modified Magnetic Resonance Observation of Cartilage Repair Tissue (M-MOCART) score and the International Cartilage Repair Society (ICRS) cartilage repair scoring system. At 2-year follow-up, clinical outcomes including VAS, IKDC, and KOOS significantly improved (P < 0.05) in both groups; however, there were no differences between two groups. There was no significant difference in M-MOCART [1-year (P = 0.261), 2-year (P = 0.351)] and ICRS repair score (P = 0.655) between two groups. Both groups showed satisfactory clinical and MRI outcomes. Implantation of MSCs from BMAC or hUCB-MSCs is safe and effective for repairing cartilage lesion. However, large cases and a well-controlled prospective design with long-term follow-up studies are needed.
机译:软骨损伤的修复生物仍然是一个显著的临床挑战。各种各样的涉及间充质干细胞(MSC)的方法已被引入。因为结果的限制,大部分的治疗方法还没有被批准的食品和药物管理局(FDA)。然而,骨髓抽吸物的浓缩物(BMAC)和人脐血间充质干细胞(人脐血间充质干)注入由韩国FDA批准。本研究的目的是在后膝骨关节炎的两种不同类型的MSC植入以评价临床和磁共振成像(MRI)的结果。谁接受使用BMAC(25个膝)和人脐血间充质干(27个膝)软骨修复手术52例(52个膝)进行回顾性评估手术后2年。根据视觉模拟评分(VAS),国际膝关节文献委员会(IKDC)主观的,并且膝关节损伤和骨关节炎结果评分(KOOS)的分数的临床结果进行了评价。软骨修复根据软骨的改性磁共振观察的修复组织(M-MOCART)评分和国际软骨修复协会(ICRS)软骨修复评分系统进行评估。在2年的随访中,临床结果,包括VAS,IKDC和KOOS显著改善两组(P <0.05);然而,两组间无显着差异。有在M-MOCART [1年(P = 0.261),2年(P = 0.351)]和两组间ICRS修复得分(P = 0.655)无显著差异。这两个群体表现出了满意的临床和MRI结果。从BMAC或人脐血间充质干的MSCs移植是安全和有效的修复软骨损伤。然而,需要大量案例和良好控制的前瞻性设计,长期随访研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号